Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02988960 · ClinicalTrials.gov registry record · Phase 1
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors Cancer, sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 163
- Enrollment target
- 20
- Study locations
NCT02988960: Active Phase 1 study of Advanced Solid Tumors Cancer, sponsored by AbbVie.
NCT02988960 is a Phase 1 study of Advanced Solid Tumors Cancer that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 163 participants, below the 336-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02988960, a Phase 1 study of Advanced Solid Tumors Cancer, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 163 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.
Primary Outcome
The MTD and the RPTD of ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 will be determined during the dose escalation phase of the study. Once the RPTD has been determined, the dose expansion portion will begin.
Conditions Studied
Interventions
- DRUG ABBV-927
- DRUG ABBV-181
Study Locations (20)
Victoria
- Peninsula Oncology Centre /ID# 164372 - Frankston
- Austin Health /ID# 171189 - Heidelberg
Other
- Yonsei University Health System Severance Hospital /ID# 166292 - Seoul
- Hospital Universitario Fundacion Jimenez Diaz /ID# 200128 - Madrid
California
- The Angeles Clinic and Researc /ID# 156324 - Los Angeles
Illinois
- The University of Chicago Medical Center /ID# 155264 - Chicago
Massachusetts
- Massachusetts General Hospital /ID# 155267 - Boston
North Carolina
- Carolina BioOncology Institute /ID# 155265 - Huntersville
Tennessee
- Tennessee Oncology-Nashville Centennial /ID# 158654 - Nashville
Texas
- University of Texas MD Anderson Cancer Center /ID# 155263 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
What the registry record for NCT02988960 still lists
NCT02988960 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, below the 336-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Advanced Solid Tumors Cancer appearing as the primary indexed condition, and to 2 interventions - of which ABBV-927 is the first listed.
NCT02988960 names 20 study sites across 18 states, led by Victoria, Other, California.
Frequently Asked Questions
What is clinical trial NCT02988960 about?
NCT02988960 is a clinical study titled "A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors". This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participa...
What is the current status of trial NCT02988960?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 163 participants. The study started on 2017-02-22. Estimated completion is 2026-09.
What conditions does trial NCT02988960 study?
This clinical trial studies the following conditions: Advanced Solid Tumors Cancer.
What interventions are being tested in trial NCT02988960?
The interventions under investigation include: ABBV-927 (DRUG), ABBV-181 (DRUG).
Who is sponsoring clinical trial NCT02988960?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02988960 being conducted?
This trial has 20 study locations across California, Illinois, Massachusetts, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02988960's enrollment target sits among peer trials
163 4th of 9 higher than 6 of 9 other Advanced Solid Tumors Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
RECRUITING · Phase 1
-
ORB-021 In Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI